Abstract
While nitrous oxide (N2O) has demonstrated antidepressant properties in treatment-resistant major depression (TRD), little is known about neural mechanisms mediating these effects. Employing serial resting-state functional magnetic resonance imaging (rs-fMRI), we compared spatiotemporal effects of inhaled N2O on brain functional connectivity in TRD patients (n=14) and non-depressed healthy controls (n=16, CNTL). Participants received sequential, one-hour inhalations of either 50% N2O/oxygen or air/oxygen (placebo), with sessions separated by at least one month in random cross-over order. BOLD-contrast rs-fMRI scans were acquired at three time points: pre-inhalation, 2 hours post-inhalation, and 24 hours post-inhalation. For the rs-fMRI functional connectivity analyses, five a priori seeds in medial limbic structures targeted cortical networks implicated in major depression – the salience, anterior and posterior default mode, reward, and cingulo-opercular networks – and a nexus in the dorsal paracingulate region previously identified in MDD (“dorsal nexus”). Depression, dissociation, and psychosis assessments were made before and after inhalations. In TRD patients, functional connectivity was reduced in all seeded networks and the voxel-wise global analysis after N2O exposure. N2O progressively decreased connectivity in patients with TRD but increased connectivity in healthy controls. In TRD patients, each seeded network demonstrated post-inhalation functional connectivity reductions in the dorsal paracingulate gyrus (“dorsal nexus”). This study further elucidates neural mechanisms underlying the antidepressant properties of N2O, supporting the notion that N2O specifically alters mood-associated brain regions in the depressed brain state by reducing functional connectivity within these brain networks.
The trial was registered at ClinicalTrials.gov (NCT02994433).
One sentence summary Nitrous oxide reduces long-range functional brain connectivity in treatment-resistant major depression, which may underlie its antidepressant action.
Competing Interest Statement
CRC has received research support from the National Institute of Mental Health, Taylor Family Institute for Innovative Psychiatric Research, Brain & Behavior Research Foundation, The American Foundation for Suicide Prevention, Assurex Health Inc., August Busch IV Foundation, and Barnes-Jewish Hospital Foundation; and he is currently serving as a research consultant to LivaNova PLC and has previously served on the Sage Therapeutics Advisory Board. CFZ serves on the Scientific Advisory Board of Sage Therapeutics. PN is currently receiving or has received funding from NIMH, American Foundation for Prevention of Suicide, Brain & Behavior Research Foundation, and has received reimbursement as advisory board member for Becton-Dickinson unrelated to this work and has previously filed for intellectual property protection related to the use of nitrous oxide in major depression (Compositions and methods for treating depressive disorders, US20170071975A1). All other authors declare that they have no competing interests. All other authors declare that they have no competing interests.
Clinical Trial
NCT02994433
Funding Statement
This work was supported by National Institute of Mental Health R21MH108901 (CRC, PN), P50MH122379 (CFZ), Taylor Family Institute for Innovative Psychiatry Research (CRC and CFZ, 1U01MH128483 (BJAP), Washington University Center for Perioperative Mental Health grant number P50 MH122351 (BJAP), and University of Chicago (PN).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Washington University School of Medicine Human Research Protection Office gave ethical approval for this work and the study was prospectively registered on ClinicalTrials.gov (Identifier NCT02994433). Written informed consent was obtained from all study participants prior to any study activities and remuneration was provided for participants time and effort.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data associated with the study are present in the paper or the Supplementary Materials.
